Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17544

Yoshihiro Ueda, Kanji Mori, Shingo Ohira, Kazuo Tarutani, Naoyuki Kanayama, Ayako Okamura, Koji Konishi

{"title":"Dosimetric Comparison of Brain Sparing Between HyperArc and GammaKnife for Single to Triple Brain Metastases.","authors":"Yoshihiro Ueda, Kanji Mori, Shingo Ohira, Kazuo Tarutani, Naoyuki Kanayama, Ayako Okamura, Koji Konishi","doi":"10.21873/anticanres.17544","DOIUrl":null,"url":null,"abstract":"Background/aim: A novel linac-bases radiosurgery (SRS) system, HyperArc, applied to the non-coplanar volume-modulated arc therapy (VMAT) technique, was developed and released in clinical practice. The aim of the study was to evaluate the dosimetric performance of brain sparing in single-target to three-target cases, for two types of SRS systems: GammaKnife and HyperArc.Patients and methods: A total of 83 patients treated with GammaKnife SRS (35 with single, 24 with double, and 24 with triple metastases) were retrospectively analyzed. Treatment plans were recalculated using HyperArc. Dosimetric parameters, including conformity index (CI), gradient index (GI), and brain volume receiving 2-20 Gy (V2-V20), were compared between the two systems.Results: No significant difference in D99 of the planning target volume (PTV) was observed between GammaKnife and HyperArc. HyperArc exhibited superior CI100, with values approaching 1.0. V4-V20 for the whole brain minus PTV were significantly lower for HyperArc than GammaKnife. In single-target cases, GI was significantly lower for HyperArc, while in triple-target cases, it was higher. V12 volumes for HyperArc were comparable to those for GammaKnife, even in cases with volumes <1.0 cm3.Conclusion: HyperArc demonstrated dosimetric performance comparable to or better than GammaKnife in brain sparing for single-to-triple metastases. These findings support HyperArc as an effective alternative for SRS planning.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1631-1641"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: A novel linac-bases radiosurgery (SRS) system, HyperArc, applied to the non-coplanar volume-modulated arc therapy (VMAT) technique, was developed and released in clinical practice. The aim of the study was to evaluate the dosimetric performance of brain sparing in single-target to three-target cases, for two types of SRS systems: GammaKnife and HyperArc.

Patients and methods: A total of 83 patients treated with GammaKnife SRS (35 with single, 24 with double, and 24 with triple metastases) were retrospectively analyzed. Treatment plans were recalculated using HyperArc. Dosimetric parameters, including conformity index (CI), gradient index (GI), and brain volume receiving 2-20 Gy (V₂-V₂₀), were compared between the two systems.

Results: No significant difference in D₉₉ of the planning target volume (PTV) was observed between GammaKnife and HyperArc. HyperArc exhibited superior CI₁₀₀, with values approaching 1.0. V₄-V₂₀ for the whole brain minus PTV were significantly lower for HyperArc than GammaKnife. In single-target cases, GI was significantly lower for HyperArc, while in triple-target cases, it was higher. V₁₂ volumes for HyperArc were comparable to those for GammaKnife, even in cases with volumes <1.0 cm³.

Conclusion: HyperArc demonstrated dosimetric performance comparable to or better than GammaKnife in brain sparing for single-to-triple metastases. These findings support HyperArc as an effective alternative for SRS planning.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.